FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379340587> ?p ?o ?g. }

• W4379340587 endingPage "e21149" @default.
• W4379340587 startingPage "e21149" @default.
• W4379340587 abstract "e21149 Background: The identification of targetable molecular tumor markers in patients (pts) with NSCLC has increased significantly over the past decades and has resulted in important changes to individual treatment approaches. One such marker is KRAS G12C for which a specific treatment is now available following prior systemic therapy. While ICIs ± chemotherapy represent first-line (1L) standard of care, the sequence of subsequent effective therapies still needs to be investigated. Methods: Cohort C of the ongoing, prospective, non-interventional VARGADO study (NCT02392455) is investigating the combination of NIN + DOC as second-line (2L) treatment after prior 1L ICI + chemotherapy in pts with adenocarcinoma NSCLC. This updated analysis of Cohort C focuses on the safety and efficacy of NIN + DOC according to programmed death ligand-1 (PD-L1) and KRAS status. Results: At the cut-off date (December 1, 2022) 219 pts have been enrolled to Cohort C. Median age was 64 years (range: 37–84) and 58.9% (129/219) of pts were men. At baseline, 30.6% (67/219) were ECOG PS 0 and 50.2% (110/219) were ECOG PS 1. 88.1% (193/219) had stage IV disease. Brain metastases were present in 19.2% (42/219) of pts and 88.1% (193/219) had received prior 1L pembrolizumab-based combination therapy. In the overall population, median PFS was 4.5 months (mo; 95% CI: 3.6–5.3, 219 pts) and median OS was 9.6 mo (95% CI: 6.5–11.2, 217 pts) with NIN + DOC. KRAS mutation status has been documented for 119 pts. In KRAS wild-type pts (75/119), median PFS was 3.7 mo (95% CI: 2.6–5.3) and median OS was 7.7 mo (95% CI: 5.2-11.2). In KRAS mutation-positive pts (44/119) median PFS was 5.1 mo (95% CI: 3.4–6.3) and median OS was 6.7 mo (95% CI: 5.3–15.1). In 33 pts with a non-G12C KRAS mutation, median PFS was 5.0 mo (95% CI: 3.4–6.7) and median OS was 6.7 mo (95% CI: 5.3–15.1). ORR was 20.0% (15/75), 25.0% (11/44), 27.3% (9/33) and 18.2% (2/11) in pts with KRAS wild-type, KRAS mutated, non-G12C mutated and G12C mutated status, respectively. The corresponding disease control rates (DCR) were 45.3% (34/75), 47.7% (21/44), 48.5% (16/33) and 45.5% (5/11). PD-L1 status prior to 1L therapy was < 1% in 86 pts and ≥1% in 76 pts and did not impact OS (median 10.6 mo [95% CI: 6.5–15.1] and 10.5 mo [95% CI: 5.7–12.5], respectively) or DCR (51.2% and 51.3%, respectively) with NIN + DOC. The most frequent NIN-related adverse events of any grade in the overall population were diarrhea 34.7% (76/219), nausea 14.2% (31/219), vomiting 8.2% (18/219) and fatigue 7.8% (17/219). Conclusions: NIN + DOC is an effective and safe 2L treatment option after prior 1L ICI + chemotherapy for NSCLC adenocarcinoma pts independent of PD-L1 and KRAS status. Clinical trial information: NCT02392455 ." @default.
• W4379340587 created "2023-06-05" @default.
• W4379340587 creator A5015898233 @default.
• W4379340587 creator A5032314001 @default.
• W4379340587 creator A5040589443 @default.
• W4379340587 creator A5041215775 @default.
• W4379340587 creator A5041857102 @default.
• W4379340587 creator A5043019017 @default.
• W4379340587 creator A5067921018 @default.
• W4379340587 creator A5072140218 @default.
• W4379340587 creator A5074420045 @default.
• W4379340587 creator A5079085915 @default.
• W4379340587 creator A5082092472 @default.
• W4379340587 creator A5087787245 @default.
• W4379340587 date "2023-06-01" @default.
• W4379340587 modified "2023-10-18" @default.
• W4379340587 title "Impact of PD-L1 and <i>KRAS</i> status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial." @default.
• W4379340587 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e21149" @default.
• W4379340587 hasPublicationYear "2023" @default.
• W4379340587 type Work @default.
• W4379340587 citedByCount "0" @default.
• W4379340587 crossrefType "journal-article" @default.
• W4379340587 hasAuthorship W4379340587A5015898233 @default.
• W4379340587 hasAuthorship W4379340587A5032314001 @default.
• W4379340587 hasAuthorship W4379340587A5040589443 @default.
• W4379340587 hasAuthorship W4379340587A5041215775 @default.
• W4379340587 hasAuthorship W4379340587A5041857102 @default.
• W4379340587 hasAuthorship W4379340587A5043019017 @default.
• W4379340587 hasAuthorship W4379340587A5067921018 @default.
• W4379340587 hasAuthorship W4379340587A5072140218 @default.
• W4379340587 hasAuthorship W4379340587A5074420045 @default.
• W4379340587 hasAuthorship W4379340587A5079085915 @default.
• W4379340587 hasAuthorship W4379340587A5082092472 @default.
• W4379340587 hasAuthorship W4379340587A5087787245 @default.
• W4379340587 hasConcept C121608353 @default.
• W4379340587 hasConcept C126322002 @default.
• W4379340587 hasConcept C141071460 @default.
• W4379340587 hasConcept C143998085 @default.
• W4379340587 hasConcept C2776694085 @default.
• W4379340587 hasConcept C2776907518 @default.
• W4379340587 hasConcept C2777701055 @default.
• W4379340587 hasConcept C2780057760 @default.
• W4379340587 hasConcept C2781187634 @default.
• W4379340587 hasConcept C2781190966 @default.
• W4379340587 hasConcept C2908647359 @default.
• W4379340587 hasConcept C526805850 @default.
• W4379340587 hasConcept C71924100 @default.
• W4379340587 hasConcept C72563966 @default.
• W4379340587 hasConcept C90924648 @default.
• W4379340587 hasConcept C99454951 @default.
• W4379340587 hasConceptScore W4379340587C121608353 @default.
• W4379340587 hasConceptScore W4379340587C126322002 @default.
• W4379340587 hasConceptScore W4379340587C141071460 @default.
• W4379340587 hasConceptScore W4379340587C143998085 @default.
• W4379340587 hasConceptScore W4379340587C2776694085 @default.
• W4379340587 hasConceptScore W4379340587C2776907518 @default.
• W4379340587 hasConceptScore W4379340587C2777701055 @default.
• W4379340587 hasConceptScore W4379340587C2780057760 @default.
• W4379340587 hasConceptScore W4379340587C2781187634 @default.
• W4379340587 hasConceptScore W4379340587C2781190966 @default.
• W4379340587 hasConceptScore W4379340587C2908647359 @default.
• W4379340587 hasConceptScore W4379340587C526805850 @default.
• W4379340587 hasConceptScore W4379340587C71924100 @default.
• W4379340587 hasConceptScore W4379340587C72563966 @default.
• W4379340587 hasConceptScore W4379340587C90924648 @default.
• W4379340587 hasConceptScore W4379340587C99454951 @default.
• W4379340587 hasIssue "16_suppl" @default.
• W4379340587 hasLocation W43793405871 @default.
• W4379340587 hasOpenAccess W4379340587 @default.
• W4379340587 hasPrimaryLocation W43793405871 @default.
• W4379340587 hasRelatedWork W1948677875 @default.
• W4379340587 hasRelatedWork W2013653877 @default.
• W4379340587 hasRelatedWork W2119002966 @default.
• W4379340587 hasRelatedWork W2420841572 @default.
• W4379340587 hasRelatedWork W2476332031 @default.
• W4379340587 hasRelatedWork W2557996697 @default.
• W4379340587 hasRelatedWork W2591035804 @default.
• W4379340587 hasRelatedWork W2743577629 @default.
• W4379340587 hasRelatedWork W2796582438 @default.
• W4379340587 hasRelatedWork W4294740325 @default.
• W4379340587 hasVolume "41" @default.
• W4379340587 isParatext "false" @default.
• W4379340587 isRetracted "false" @default.
• W4379340587 workType "article" @default.